arrow
R

Roberto Barriales-Villa

hospital universitario de a coruna
H指数:39
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM

梗阻性肥厚型心肌病患者报告结局指标的长期影响:FOREST-HCM研究的结果

2026-08-030
OAAI
Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy

mavacamten 在人类和鼠类 MYBPC3 相关肥厚型心肌病模型中显示出广泛益处

2026-07-070
PRE
Association of genotype with treatment response and prognosis in dilated cardiomyopathy

扩张型心肌病中基因型与治疗反应及预后的关联

2026-05-011
OA
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial

Aficamten在梗阻性肥厚型心肌病中的应用:MAPLE-HCM试验的多领域、患者水平分析

JACC
IF0
2025-11-180
OAAI
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy

Aficamten与Metoprolol对梗阻性肥厚型心肌病患者自报健康状态的影响

JACC
IF0
2025-11-180
OAAI
Danicamtiv, a selective agonist of cardiac myosin, for dilated cardiomyopathy: A Phase 2 open-label trial

Danicamtiv,一种心脏肌球蛋白选择性激动剂,用于扩张型心肌病:一项II期开放标签试验

JACC
IF0
2025-09-290
OAAI
Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM

Aficamten在非梗阻性肥厚型心肌病患者的安全性与有效性:FOREST-HCM研究96周分析

2025-09-280
OAAI
Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis from the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials

梗阻性肥厚型心肌病患者使用Aficamten治疗后房颤发生率低:REDWOOD-HCM、SEQUOIA-HCM和FOREST-HCM试验的分析

2025-08-310
OAAI
Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM

与美托洛尔相比,阿菲卡姆坦对症状性梗阻性肥厚型心肌病超声心动图指标的影响:MAPLE-HCM

JACC
IF0
2025-08-270
PREAI
Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy

Mavacamten对非梗阻性肥厚型心肌病心脏生物标志物的影响

JACC
IF0
2025-08-270
PRE
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten 治疗:有症状性梗阻性肥厚型心肌病

2025-06-190
PRE
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial

阿菲坎坦在梗阻性肥厚型心肌病伴轻度症状患者中的疗效:SEQUOIA-HCM试验结果

2025-05-012
OAAI
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy

TNNT2基因中的p.Asn271Ile变异与低风险迟发性肥厚型心肌病相关联

2025-04-300
PRE
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy

阿菲坎坦与丙吡胺联用治疗症状性梗阻性肥厚型心肌病

2025-04-020
OAAI
Electrophysiological Phenotype-Genotype Study of Sustained Monomorphic Ventricular Tachycardia in Inherited, High Arrhythmic Risk, Left Ventricular Cardiomyopathy
2024-12-010
PRE
Efficacy and Safety of Aficamten in Patients Guideline-Eligible for Septal Reduction Therapy in the FOREST-HCM Trial

Aficamten在FOREST-HCM试验中,对符合室间隔减容治疗指南适应证患者的疗效与安全性

2024-11-120
PRE